(Q43515674)

English

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

cerebrospinal fluid

0 references

pharmacogenomics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Masahide Fukudo

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yasuaki Ikemi

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yosuke Togashi

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Katsuhiro Masago

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Young Hak Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Tadashi Mio

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Tomohiro Terada

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Satoshi Teramukai

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Michiaki Mishima

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Ken-Ichi Inui

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Toshiya Katsura

11

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

593-609

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Erlotinib and gastrointestinal ulcer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

FDA drug approval summary: erlotinib (Tarceva) tablets

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0058-5

21 January 2018

Effects of smoking on the pharmacokinetics of erlotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-013-0058-5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43515674&oldid=2206095555"